In a report released today, Greg Palm from Craig-Hallum maintained a Hold rating on Desktop Metal (DM – Research Report). The company’s shares closed yesterday at $0.61.
According to TipRanks, Palm is a 5-star analyst with an average return of 9.9% and a 52.94% success rate. Palm covers the Technology sector, focusing on stocks such as Faro Technologies, 3D Systems, and nLIGHT.
The word on The Street in general, suggests a Hold analyst consensus rating for Desktop Metal with a $0.85 average price target, implying a 39.32% upside from current levels. In a report released yesterday, Lake Street also maintained a Hold rating on the stock with a $0.85 price target.
See today’s best-performing stocks on TipRanks >>
DM market cap is currently $198.1M and has a P/E ratio of -0.42.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DM in relation to earlier this year. Earlier this month, EBRAHIMI FARHAD FRED, a Major Shareholder at DM bought 5,298,200.00 shares for a total of $9,254,600.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Desktop Metal (DM) Company Description:
Trine Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on September 26, 2018 and is headquartered in New York, NY.
Read More on DM:
- Desktop Metal Announces Initiative in Regulation FD Disclosure
- Desktop Metal Announces Major Cost Optimization Initiative
- Desktop Metal announces additional $50M in cost reduction, workforce cuts
- Largest borrow rate increases among liquid names
- Desktop Health says first patients treated with FDA-cleared CMFlex
